Drug Trial Radar · NCT04905667
Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®
Last checked: Nov 19, 2026Latest source record: May 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Nov 13, 2019
Primary completion
Sep 8, 2020
Study completion Sep 11, 2020
Sponsor
- Lead sponsor
- Genor Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center, randomized, blind, parallel controlled clinical trial. The primary objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2 monoclonal antibody injection GB221 in comparison with Herceptin ® in Chinese healthy adult volunteers. The main aim is to study the pharmacokinetic similarity between GB221 and Herceptin ®.
Conditions
- Breast Cancer
Interventions
GB221Drug
6 mg/kg, single dose, intravenous infusion, 90-100 min
HerceptinDrug
6 mg/kg, single dose, intravenous infusion, 90-100 min
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-tTime frame: Day 43
- AUC0-∞Time frame: Day 43
- CmaxTime frame: Day 43
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Fifth Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.